Spyre Therapeutics (SYRE) stock analysis: de-risked pipeline, cash runway to H2 2028, and 2026–2027 Phase 2 catalysts in ...

Rezdiffra FDA approval fuels sales; expansion to F4 MASH cirrhosis with 2027 trial data. Read more about MDGL stock here.

SynuSight Biotech has licensed 18 F-FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein clearance from the brain in response to risvodetinib treatment . SHANGH ...

Vanda also sells sleep disorder drug Hetlioz, which reached the market in 2014, and relapsing multiple sclerosis treatment Ponvory, which was approved in 2021. The FDA is scheduled on Jan. 7 to decide ...

Alcaide is referring to the need for an elaborate helmet and even conductive gel to get good EEG readings in many cases, but ...

TORONTO and HOUSTON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the ...

AstraZeneca announces Saphnelo self-administration phase III TULIP-SC trial demonstrates statistically significant and clinically meaningful reduction in SLE disease activity ...

Scientists at the Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, have captured real-time images showing how a key brain enzyme organizes itself to help memory formation. Their study, ...

Detailed price information for Medicenna Therapeutics Corp (MDNAF) from The Globe and Mail including charting and trades.

In the expansive world of regenerative medicine and biochemistry, few molecules have generated as much sustained excitement ...

VANCOUVER, British Columbia & GRAPEVINE, Texas, January 07, 2026--Alpha Cognition, Inc. (the "Company", "we", "us" and "ours") (NASDAQ: ACOG), a commercial-stage neuroscience company focused on ...